negative impacts of glp 1 The expanding role GLP-1 receptor agonists: a narrative review of current evidence and future directions Long-term Success of GLP-1s Hinges

High-dose use While trials have tested up to 1200mg/day (even as high as 2400mg/day) and illustrated safety, some report higher rates of gastrointestinal side effects, dizziness, and skin reactions at these levels.14 28 38 Additionally, these higher doses are often short-term (35 weeks) and used under clinical supervision

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes mellitus, though certain formulations are now licensed for weight management in adults with obesity or overweight with weight-related comorbidities

APAP administered intraperitoneally to mice (250 mg/kg) shows that mitochondrial GSH depletion appears to be more severe than cytoplasmic depletion (Tirmenstein and Nelson, 1989)

"I accepted it

Without clear symptoms, a level of 150-187ng/L would trigger a repeat test and an oral trial of treatment only if the borderline low result persisted